Servicio de Oncología Médica, Hospital Arnau de Vilanova, Valencia, Spain.
Clin Transl Oncol. 2009 Nov;11(11):727-36. doi: 10.1007/s12094-009-0435-6.
Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in nonresponders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended.
贫血的治疗是癌症患者管理中的一个非常重要的方面。为了就红细胞生成刺激剂（ESA）在癌症患者中的应用达成共识，西班牙肿瘤医学学会（SEOM）成立了一个工作组，协调了一组肿瘤医学专家。该工作组审查了关于ESA 使用的主要问题。此外，还于 2007 年 4 月 25 日在马德里举行了一次共识会议。会议做出如下结论：由于 ESA 治疗可提高血红蛋白（Hb）水平并减少红细胞（RBC）输血需求，因此应在化疗治疗患者的批准适应证内使用 ESA，起始 Hb 水平低于 11g/dl 并维持在 12g/dl 左右，如果需要则补充铁剂。不建议增加无反应者的 ESA 剂量，也不建议在治疗慢性癌症相关贫血时使用 ESA。
